459 related articles for article (PubMed ID: 29734251)
1. MYD88, CARD11, and CD79B Oncogenic Mutations are Rare Events in the Indian Cohort of De Novo Nodal Diffuse Large B-Cell Lymphoma.
Aggarwal V; Das A; Bal A; Srinivasan R; Das R; Prakash G; Malhotra P; Varma S
Appl Immunohistochem Mol Morphol; 2019 Apr; 27(4):311-318. PubMed ID: 29734251
[TBL] [Abstract][Full Text] [Related]
2. MYD88, CD79B, and CARD11 gene mutations in CD5-positive diffuse large B-cell lymphoma.
Takeuchi T; Yamaguchi M; Kobayashi K; Miyazaki K; Tawara I; Imai H; Ono R; Nosaka T; Tanaka K; Katayama N
Cancer; 2017 Apr; 123(7):1166-1173. PubMed ID: 27915469
[TBL] [Abstract][Full Text] [Related]
3. Frequent MYD88 L265P and CD79B Mutations in Primary Breast Diffuse Large B-Cell Lymphoma.
Taniguchi K; Takata K; Chuang SS; Miyata-Takata T; Sato Y; Satou A; Hashimoto Y; Tamura M; Nagakita K; Ohnishi N; Noujima-Harada M; Tabata T; Kikuti YY; Maeda Y; Nakamura N; Tanimoto M; Yoshino T
Am J Surg Pathol; 2016 Mar; 40(3):324-34. PubMed ID: 26752547
[TBL] [Abstract][Full Text] [Related]
4. Prevalence of targetable oncogenic mutations and genomic alterations in Epstein-Barr virus-associated diffuse large B-cell lymphoma of the elderly.
Gebauer N; Gebauer J; Hardel TT; Bernard V; Biersack H; Lehnert H; Rades D; Feller AC; Thorns C
Leuk Lymphoma; 2015 Apr; 56(4):1100-6. PubMed ID: 25030036
[TBL] [Abstract][Full Text] [Related]
5. Adaptive T-cell immunity controls senescence-prone MyD88- or CARD11-mutant B-cell lymphomas.
Reimann M; Schrezenmeier J; Richter-Pechanska P; Dolnik A; Hick TP; Schleich K; Cai X; Fan DNY; Lohneis P; Maßwig S; Denker S; Busse A; Knittel G; Flümann R; Childs D; Childs L; Gätjens-Sanchez AM; Bullinger L; Rosenwald A; Reinhardt HC; Schmitt CA
Blood; 2021 May; 137(20):2785-2799. PubMed ID: 33232972
[TBL] [Abstract][Full Text] [Related]
6. CD79B and MYD88 mutations in diffuse large B-cell lymphoma.
Kim Y; Ju H; Kim DH; Yoo HY; Kim SJ; Kim WS; Ko YH
Hum Pathol; 2014 Mar; 45(3):556-64. PubMed ID: 24444466
[TBL] [Abstract][Full Text] [Related]
7. Frequency of MYD88 and CD79B mutations, and MGMT methylation in primary central nervous system diffuse large B-cell lymphoma.
Zheng M; Perry AM; Bierman P; Loberiza F; Nasr MR; Szwajcer D; Del Bigio MR; Smith LM; Zhang W; Greiner TC
Neuropathology; 2017 Dec; 37(6):509-516. PubMed ID: 28856744
[TBL] [Abstract][Full Text] [Related]
8. Morphologic Patterns and the Correlation With MYD88 L265P, CD79B Mutations in Primary Adrenal Diffuse Large B-Cell Lymphoma.
Chen Z; Zou Y; Liu W; Guan P; Tao Q; Xiang C; Zhang W; Ye Y; Yan J; Zhao S
Am J Surg Pathol; 2020 Apr; 44(4):444-455. PubMed ID: 31609782
[TBL] [Abstract][Full Text] [Related]
9. Activating mutations affecting the NF-kappa B pathway and EZH2-mediated epigenetic regulation are rare events in primary mediastinal large B-cell lymphoma.
Gebauer N; Hardel TT; Gebauer J; Bernard V; Merz H; Feller AC; Rades D; Biersack H; Lehnert H; Thorns C
Anticancer Res; 2014 Oct; 34(10):5503-7. PubMed ID: 25275047
[TBL] [Abstract][Full Text] [Related]
10. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma.
Davis RE; Ngo VN; Lenz G; Tolar P; Young RM; Romesser PB; Kohlhammer H; Lamy L; Zhao H; Yang Y; Xu W; Shaffer AL; Wright G; Xiao W; Powell J; Jiang JK; Thomas CJ; Rosenwald A; Ott G; Muller-Hermelink HK; Gascoyne RD; Connors JM; Johnson NA; Rimsza LM; Campo E; Jaffe ES; Wilson WH; Delabie J; Smeland EB; Fisher RI; Braziel RM; Tubbs RR; Cook JR; Weisenburger DD; Chan WC; Pierce SK; Staudt LM
Nature; 2010 Jan; 463(7277):88-92. PubMed ID: 20054396
[TBL] [Abstract][Full Text] [Related]
11. Combinatorial BTK and MALT1 inhibition augments killing of CD79 mutant diffuse large B cell lymphoma.
Nagel D; Bognar M; Eitelhuber AC; Kutzner K; Vincendeau M; Krappmann D
Oncotarget; 2015 Dec; 6(39):42232-42. PubMed ID: 26540570
[TBL] [Abstract][Full Text] [Related]
12. Primary diffuse large B-cell lymphomas of central nervous system exhibit remarkably high prevalence of oncogenic MYD88 and CD79B mutations.
Yamada S; Ishida Y; Matsuno A; Yamazaki K
Leuk Lymphoma; 2015 Jul; 56(7):2141-5. PubMed ID: 25347427
[TBL] [Abstract][Full Text] [Related]
13. MYD88 expression and L265P mutation in diffuse large B-cell lymphoma.
Choi JW; Kim Y; Lee JH; Kim YS
Hum Pathol; 2013 Jul; 44(7):1375-81. PubMed ID: 23380077
[TBL] [Abstract][Full Text] [Related]
14. Lymphomagenic CARD11/BCL10/MALT1 signaling drives malignant B-cell proliferation via cooperative NF-κB and JNK activation.
Knies N; Alankus B; Weilemann A; Tzankov A; Brunner K; Ruff T; Kremer M; Keller UB; Lenz G; Ruland J
Proc Natl Acad Sci U S A; 2015 Dec; 112(52):E7230-8. PubMed ID: 26668357
[TBL] [Abstract][Full Text] [Related]
15. Targetable activating mutations are very frequent in GCB and ABC diffuse large B-cell lymphoma.
Bohers E; Mareschal S; Bouzelfen A; Marchand V; Ruminy P; Maingonnat C; Ménard AL; Etancelin P; Bertrand P; Dubois S; Alcantara M; Bastard C; Tilly H; Jardin F
Genes Chromosomes Cancer; 2014 Feb; 53(2):144-53. PubMed ID: 24327543
[TBL] [Abstract][Full Text] [Related]
16. Role of nuclear factor-κB regulators TNFAIP3 and CARD11 in Middle Eastern diffuse large B-cell lymphoma.
Bu R; Bavi P; Abubaker J; Jehan Z; Al-Haqawi W; Ajarim D; Al-Dayel F; Uddin S; Al-Kuraya KS
Leuk Lymphoma; 2012 Oct; 53(10):1971-7. PubMed ID: 22397314
[TBL] [Abstract][Full Text] [Related]
17. CARMA1- and MyD88-dependent activation of Jun/ATF-type AP-1 complexes is a hallmark of ABC diffuse large B-cell lymphomas.
Juilland M; Gonzalez M; Erdmann T; Banz Y; Jevnikar Z; Hailfinger S; Tzankov A; Grau M; Lenz G; Novak U; Thome M
Blood; 2016 Apr; 127(14):1780-9. PubMed ID: 26747248
[TBL] [Abstract][Full Text] [Related]
18. Oncogenic CARMA1 couples NF-κB and β-catenin signaling in diffuse large B-cell lymphomas.
Bognar MK; Vincendeau M; Erdmann T; Seeholzer T; Grau M; Linnemann JR; Ruland J; Scheel CH; Lenz P; Ott G; Lenz G; Hauck SM; Krappmann D
Oncogene; 2016 Aug; 35(32):4269-81. PubMed ID: 26776161
[TBL] [Abstract][Full Text] [Related]
19. Cooperative Control of Caspase Recruitment Domain-containing Protein 11 (CARD11) Signaling by an Unusual Array of Redundant Repressive Elements.
Jattani RP; Tritapoe JM; Pomerantz JL
J Biol Chem; 2016 Apr; 291(16):8324-36. PubMed ID: 26884335
[TBL] [Abstract][Full Text] [Related]
20. Biological and Clinical Relevance of Associated Genomic Alterations in MYD88 L265P and non-L265P-Mutated Diffuse Large B-Cell Lymphoma: Analysis of 361 Cases.
Dubois S; Viailly PJ; Bohers E; Bertrand P; Ruminy P; Marchand V; Maingonnat C; Mareschal S; Picquenot JM; Penther D; Jais JP; Tesson B; Peyrouze P; Figeac M; Desmots F; Fest T; Haioun C; Lamy T; Copie-Bergman C; Fabiani B; Delarue R; Peyrade F; André M; Ketterer N; Leroy K; Salles G; Molina TJ; Tilly H; Jardin F
Clin Cancer Res; 2017 May; 23(9):2232-2244. PubMed ID: 27923841
[No Abstract] [Full Text] [Related]
[Next] [New Search]
